ASH 2017 | Results of the TRANSCEND study of CAR T Cell Product JCAR017 in patients with R/R aggressive B-NHL

Jeremy Abramson

Dr Jeremy Abramson, MD, from the Massachusetts General Hospital, Boston, MA, gives us a detailed presentation of progress in the TRANSCEND-NHL-001 trial (NCT02631044) presented at the ASH 2017 meeting in Atlanta, GA. He covers the rationale, design, results and safety profile as well as giving us his opinion on the data.

Share this video